Viridian Therapeutics

company

About

Viridian Therapeutics discovers and develops innovative microRNA-targeting therapies to improve human health.

  • 51 - 100

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$75M
Industries
Biotechnology,Genetics,Health Care,Therapeutics
Founded date
Jan 1, 2007
Number Of Employee
51 - 100
Operating Status
Active

Viridian Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. Viridian is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$79M
Viridian Therapeutics has raised a total of $79M in funding over 2 rounds. Their latest funding was raised on Apr 4, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 4, 2022 Post-IPO Debt $75M 1 Hercules Capital Detail
Jun 3, 2009 Series A $4M 1 Detail

Investments

Number of Investments
Number of Lead Investments
1
1
Viridian Therapeutics has made 1 investments. Their most recent investment was on Sep 3, 2015, when Tala raised $10M.
Date Company Name
Round Money Raised Industry Lead Investor
Sep 3, 2015 Tala
Series A $10M Analytics Yes

Investors

Number of Lead Investors
Number of Investors
1
2
Viridian Therapeutics is funded by 2 investors. Hercules Capital and The Peierls Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Post-IPO Debt
The Peierls Foundation Series A